The diagnostics company Gradientech today announces that its QuickMIC[®] diagnostic test for ultra-rapid antibiotic susceptibility testing (AST) of sepsis samples, has been officially certified under the European Union’s In Vitro Diagnostic Medical Device Regulation (IVDR) – the new stringent regulatory framework for diagnostic devices.
The diagnostics company Gradientech today announces a new scientific publication confirming the QuickMIC® system to deliver accurate antibiotic susceptibility testing (AST) results up to 75% faster than current gold-standards automated solutions, enabling faster treatment decision for sepsis and blood stream infections. The clinical data is published in the high-ranked European Journal of Clinical Microbiology & Infectious Diseases.
Diagnostikföretaget Gradientech meddelar idag publiceringen av en ny vetenskaplig studie som ytterligare stärker bevisläget för företagets QuickMIC®-system för ultrasnabb antibiotikaresistensbestämning (AST). Studien visar att systemet levererar tillförlitliga resultat upp till 75 procent snabbare än dagens automatiserade standardmetoder – ett genombrott som kan möjliggöra snabbare behandlingsbeslut vid sepsis och blodinfektioner.
The diagnostics company Gradientech today announces the collaboration with Vienna-based Cellectric on a new proof-of-concept study of a direct-from-blood application to speed up sepsis diagnostic workflows.
Diagnostikföretaget Gradientech tillkännager idag samarbetet med Wien-baserade Cellectric kring en ny förstudie av en metod för analys direkt från blod för att påskynda arbetsflöden inom sepsisdiagnostik.
Diagnostikföretaget Gradientech meddelar idag att en ny expertgranskad vetenskaplig studie publicerats av den välrenommerade italienska forskargruppen som leds av professor Gian Maria Rossolini. Studien visar på prestandan hos QuickMIC[®]-systemet för ultrasnabb antibiotikaresistensbestämning (AST).
The diagnostics company Gradientech today announces the publication of a new peer-reviewed scientific study led by the renowned Italian research group of Professor Gian Maria Rossolini, showcasing the performance of the QuickMIC[®] system for ultra-rapid antibiotic susceptibility testing (AST).
Gradientech AB (publ) interim report for Q2 2025 is now available on the company’s website www.gradientech.se.
Gradientech AB (publ) delårsrapport för Q2 2025 är nu tillgänglig på bolagets hemsida www.gradientech.se.
The diagnostics company Gradientech today announces to have been awarded the Clinical Diagnostics Campaign of the Year at the prestigious Scientists’ Choice Awards® 2025, presented by SelectScience® during the ADLM 2025 (Association for Diagnostics & Laboratory Medicine) conference in Chicago, US.